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Abstract
Background: The purpose of this study was to investigate peripapillary choroidal thickness (CT) in eyes with neovascular
age-related macular degeneration (AMD) and to assess whether peripapillary CT is affected by intravitreal injection of
ranibizumab (IVR) in eyes with neovascular AMD.
Methods: Peripapillary and subfoveal CT were measured in spectral domain optical coherence tomography images from
39 eyes of neovascular AMD patients and 39 eyes of age-matched controls retrospectively. The patients were treated with
0.5 mg IVR monthly for 3 months and retreated as needed. Peripapillary CT at baseline, 3 months and 6 months was
measured at four locations (superior, nasal, inferior and temporal areas).
Results: The mean peripapillary and subfoveal baseline CTs of the eyes with neovascular AMD (153.3 ± 45.3 μm and
228.6 ± 78.6 μm) were not different from those of the controls (149.0 ± 42.3 μm and 221.4 ± 54.1 μm; P = 0.665 and
P = 0.639, respectively). Subfoveal CT decreased at 3 months (213.8 ± 75.8 μm, P < 0.001) and 6 months (215.1 ± 72.8 μm,
P = 0.002) following IVR treatment. Mean peripapillary CT did not show significant changes at 3 months (149.6 ± 43.8 μm,
P = 0.156) or 6 months (150.0 ± 43.4 μm, P = 0.187). Subanalysis revealed that only temporal peripapillary CT decreased
from baseline (167.1 ± 54.5 μm) to 3 months (159.4 ± 50.8 μm, P = 0.010) and was sustained at 6 months (160.6 ± 49.6,
P = 0.026). However, superior, nasal and inferior peripapillary CT did not show significant changes after IVR.
Conclusions: Changes in peripapillary CT after IVR were limited to the macular area. This result may suggest that IVR does
not affect CT outside of the macula in the eyes of patients with neovascular AMD.
Keywords: Age-related macular degeneration, Choroidal thickness, Optical coherence tomography, Peripapillary choroidal
thickness, Ranibizumab
Background
Age-related macular degeneration (AMD) is a leading
cause of vision loss in the elderly worldwide [1]. With the
development and introduction of anti-vascular endothelial
growth factor (VEGF) therapy, the functional outcomes of
neovascular AMD have been markedly improved [2–4].
Ranibizumab (Lucentis; Genentech, Inc., San Francisco,
CA; co-developed by Genentech, Inc and Novartis), is an
FDA approved VEGF-A inhibitor that is commonly used
for the treatment of AMD [5].
Previous studies have suggested that AMD may be a
vascular disorder associated with altered blood flow in the
choroid [6, 7]. Because abnormalities in choroidal circula-
tion and structure are thought to be associated with the
pathogenesis of AMD [8, 9], there have been many studies
on choroidal thickness (CT) in AMD [10–13]. Recently,
some studies have suggested that the CT in patients with
neovascular AMD may be affected by intravitreal injection
of ranibizumab (IVR) [14, 15]. Because VEGF is known to
be associated with the maintenance of choriocapillaries
and ocular blood flow, there have been concerns regarding
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potential undesired effects of anti-VEGF therapy on the
choroid [16, 17]. However, recent studies found that CT
changes following IVR treatment for neovascular AMD
were limited to the choroid of the macular region [14, 15].
It is not certain whether CT outside the macula is affected
by IVR, and the effect of anti-VEGF therapy on CT of nor-
mal choroid without overlying retinal pathology remains
unclear [18].
The choroid is a highly vascular tissue of the eye that
supplies blood to the outer retina, retinal pigment epithe-
lium (RPE), and possibly the optic nerve head [19]. The
choroid is supplied by various ciliary arteries that originate
from the ophthalmic arteries [20]. The branches of the
posterior ciliary artery (PCA) consist of long PCAs and
short PCAs [20]. The posterior choriocapillaries in the
peripapillary and submacular region are supplied by the
short PCAs. These arteries have strictly segmental blood
flow without anastomosis and supply a well-defined sector
of the choroid [21]. The medial PCA supplies the nasal
choroid, while the lateral PCA supplies the area of the
choroid not supplied by the medial PCA [20]. Therefore,
blood flow to the nasal peripapillary choroid could differ
from the flow to the temporal peripapillary and subfoveal
choroid. Recently, several studies on the choroid outside
of the macula in retinal disease have focused on the
peripapillary choroid and the nasal peripapillary choroid
represented the choroid outside of macula [22–24]. We
hypothesized that the change in CT after IVR would differ
between the macula and areas outside of the macula. We
also investigated the peripapillary and subfoveal CT in
neovascular AMD and the change in CT after IVR
treatment.
Methods
The Institutional Review Board of Korea University
Medical center approved this study (IRB No. ED14121),
and all research and data collection was conducted in
accordance with the tenets of the Declaration of
Helsinki. We performed a retrospective case–control
study of patients 50 years of age or older who were diag-
nosed with neovascular AMD between February 2011
and March 2013 at Korea University Medical Center.
We included patients who underwent IVR for neovascu-
lar AMD. Age-matched controls were selected from the
spectral domain optical coherence tomography (SD-
OCT) database based on classification of normal eyes.
Patients with a primary diagnosis of AMD, a history of
laser photocoagulation of the macula, serous detachment
of the macula, rhegmatogenous or tractional retinal de-
tachment, high myopia, tapetoretinal degeneration, optic
disc abnormalities such as glaucoma, beta zone peripapil-
lary atrophy, or neurologic deficits were excluded from
the control group.
Neovascular AMD was diagnosed in patients who were
older than 50 and showed exudative changes from chor-
oidal neovascularization (CNV) on fluorescein angiography
(FA) and SD-OCT. This study excluded cases of polypoidal
choroidal vasculopathy (PCV). PCV was diagnosed based
on the presence of CNV on FA with characteristic findings
on SD-OCT and if any one of the following criteria were
met: 1) branching vascular networks underneath the RPE
and focal hyperfluorescent polyps were present on indocya-
nine green angiography, 2) recurrent hemorrhagic or serous
pigmented epithelial detachments were detected, or 3) the
existence of an elevated reddish-orange lesion protruding
from the choroid on fundus examination [25–28]. Neovas-
cular lesions were classified into type 1 (sub-RPE), type 2
(subretinal) or type 3 (intraretinal) according to the MPS
criteria and to the guidelines provided by Freund and
colleagues based on angiographic and OCT features
[29–31]. Classifications were independently determined
by two retina specialists (C.Y. and J.A.). Disagreements
were resolved upon further review by two observers.
Cases with refractive errors ≤ -6.0 diopters or axial
length ≥ 26.0 mm and cases with a history of cataract
surgery within the past 6 months, refractive surgery or
vitreoretinal surgery were also excluded from this study.
Patients with a history of glaucoma, optic nerve disorder,
beta zone peripapillary atrophy, retinal or choroidal dis-
order including vascular disease or uveitis and previous
treatment with photodynamic therapy or other intravitreal
anti-VEGF injection were also excluded from this study.
Images were excluded if they were found to be low quality
with a signal strength indicator (Q-factor) value < 45 or if
the choroidal layer was not visible due to severe subfoveal
hemorrhage. Data were collected at baseline, 3 months
and 6 months after IVR.
Intravitreal injection of ranibizumab
A single surgeon (JO) performed all injections. Before
intravitreal injection, local anesthesia was induced with
proxymetacaine hydrochloride drops (Alcaine 0.5 %; Alcon,
Fort Worth, TX, USA). After the periocular disinfection
procedure, the patient was draped. With lid speculum
insertion, 5 % povidone iodine was introduced on the
conjunctiva for 30 s. After injection of 0.05 ml ranibizumab
into the eye 3.5 mm from the limbus, antibiotic eye drops
were administered. After three monthly injections of IVRs,
patients were followed up every month, and retreatment
was considered if any of the following changes were ob-
served: (1) visual acuity loss with the presence of fluid in
the macula detected by OCT, (2) OCTcentral retinal thick-
ness (CRT) increased by at least 100 μm, (3) new macular
hemorrhage, or (4) persistent fluid on OCT at least 1
month after the previous IVR [32]. Responders were de-
fined as patients with a disappearance of subretinal fluid or
macular edema or those with a decrease in CRT of more
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than 100 μm on OCT 3 months after IVR as compared to
the initial visit. Non-responders were defined as those with
no change in subretinal fluid or macular edema or with a
decrease in CRT of less than 100 μm on OCT when com-
pared to the initial visit.
Spectral domain optical coherence tomography
This study used a SD-OCT (3D OCT-1000 Mark II, soft-
ware version 6.21; Topcon Corp., Tokyo, Japan) with a
wavelength of 840 nm, a horizontal resolution of less than
20 μm, and an axial resolution of up to 5 μm. Choroidal
mode was used to capture choroidal layer images. Hori-
zontal 6-mm line-scans centered on the fovea and circle
scans in a 3.4-mm zone around the optic disc were
obtained. The line scan and circle scan consisted of 1024
A-scans, and circle scan images were scanned four times.
All images were averaged to improve the signal-to-noise
ratio.
Measurement of peripapillary choroidal thickness
Peripapillary CT was measured in a 3.4-mm diameter
circle scan performed around the optic disc. The circle
scan was performed using a standard protocol for retinal
nerve fiber layer (RNFL) assessment, and the retinal
thickness (RT) and RNFL thickness was assessed in four
sectors (superior, nasal, inferior and temporal) around the
disc. The thickness value represents the mean thickness of
the layers within each sector. Peripapillary RT and RNFL
thickness were obtained through automatic segmentation
using the OCT viewer software after confirmation of
appropriately placed segmentation lines. In cases with
abnormal segmentation of the RPE or NFL due to drusen
(n = 1) or posterior hyaloid membranes (n = 3), the seg-
mentation errors were modified. Peripapillary CT was
measured using a previously reported method [22, 24, 33].
Briefly, the modification tool in the SD-OCT image viewer
program was used to move the segmentation line indicat-
ing RPE to the chorioscleral junction. With this modifica-
tion, we obtained the chorioretinal thickness between the
ILM and chorioscleral junction. Peripapillary CT was
calculated by subtracting RT from the chorioretinal thick-
ness in each sector (Fig. 1). All measurements were per-
formed by two independent blinded examiners (CY and
KC), and the mean value from the two observers was used
for analysis.
Measurement of subfoveal choroidal thickness
Choroidal layer images of the macula were obtained
using choroidal mode within the OCT with a 6-mm line
scan image centered on the fovea [12, 34]. CT measure-
ment was performed manually with a caliper tool built
in the image viewer program of SD-OCT. CT was de-
fined as the length between the outer surface of a hyper-
reflective line of the RPE and the inner margin of the
chorioscleral junction perpendicularly (Fig. 1). All mea-
surements were performed by two independent, blinded
examiners (CY and KC). The mean value from the two
observers was used for analysis.
Statistical methods
Controls were selected from the hospital OCT database
and frequency-matched to the age distribution of AMD
cases with a statistician’s assistance. If a patient had neovas-
cular AMD in both eyes, the right eye was selected for
analysis, and age matching was based on the statistician’s
discretion.
A Kolmogorov-Smirnov test was performed to determine
whether the variables demonstrated a normal distribution.
The student t-test, chi-square test and Fisher’s exact test
were used to compare the parameters between AMD pa-
tients and the controls. A paired t-test was used to analyze
the difference between the peripapillary CT, RT and RNFL
thickness means in each sector and the macular CT during
each visit. The Pearson’s correlation test was used to
analyze the relationships between parameters.
By comparing CT before and after IVR, the propor-
tional change in CT was calculated as the difference in
CT (CT at 3 months – CT at baseline) divided by CT at
baseline. The control group parameters included mean
refractive error, RT, RNFL thickness and CT of the right
eye. Statistical analyses were performed using SPSS soft-
ware version 20.0 for Windows (IBM Corp., Armonk,
NY, USA). Results were considered statistically signifi-
cant at P values < 0.05.
Results
After reviewing the medical records of 79 patients
who were diagnosed with neovascular AMD, we ex-
cluded 23 cases of PCV, two cases of high myopia,
one case of history of vitreoretinal surgery, three
cases of low quality image, six cases of glaucoma, five
cases of beta zone peripapillary atrophy. In a total of
39 eyes of 39 patients with neovascular AMD and an
equal number of controls eyes were included in this
study. Mean age at diagnosis in the neovascular AMD
group was not different from that of the control
group (Table 1). There were no differences in sex or
lens status between the two groups. The mean number
of IVRs within the 6-month period was 4.4 ± 0.9 (range,
3–6). Mean BCVA (LogMAR) of the 39 patients was 0.73
± 0.45 at baseline, 0.50 ± 0.38 at 3 months, and 0.51 ± 0.44
at 6 months. Mean BCVA values at 3 months and
6 months were significantly improved when compared to
baseline (all, P < 0.001). At baseline, the neovascular
lesions were categorized as type 2 (35 eyes, 89.7 %) and
type 3 (4 eyes, 10.3 %).
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Comparison of baseline choroidal thickness in AMD eyes
and controls
The mean peripapillary CT of the eyes in the AMD group
was not significantly different from that of the control
group (Table 2). In the control group, the mean peripapil-
lary CT correlated with age (r = - 0.415, P = 0.009), but the
mean peripapillary CT of the AMD group did not correl-
ate with age (r = - 0.169, P = 0.303).
The mean subfoveal CT of the AMD group was not
significantly different from that of the control group
(Table 2). In the control group, subfoveal CT correlated
with age (r = - 0.386, P = 0.015), but subfoveal CT in
the AMD group did not correlate with age (r = - 0.162,
P = 0.324).
Choroidal thickness after intravitreal injection of
ranibizumab
The mean peripapillary CT at baseline in the AMD group
decreased after IVR, but this was not a statistically signifi-
cant difference at 3 months or 6 months (Table 3). Among
the four sectors of the peripapillary area, only the temporal
Table 1 Baseline characteristics of patients with age-related
macular degeneration and age-matched controls
AMD group Control group P value
(n = 39) (n = 39)
Mean age at diagnosis (years) 68.8 ± 6.5 68.3 ± 6.5 0.755*
Sex (M : F) 18 : 21 16 : 23 0.648**
Lens (Phakia : Pseudophakia) 37 : 2 35 : 4 0.675**
Refractive error (D)a 0.46 ± 1.43 0.34 ± 1.64 0.734*
Type of neovascularization,
eyes (%)
Type 2 35 (89.7 %)
Type 3 4 (10.3 %)
Continuous variables are expressed as mean ± standard deviation
*P value based on student t-test
**P value based on Chi-square test or Fisher’s exact test for
categorical variables
aRefractive errors were obtained from 37 eyes in the AMD group and 35 eyes in the
control group, which included all eyes except two eyes exhibiting pseudophakia in
the AMD group and four eyes exhibiting pseudophakia in the control group
AMD age-related macular degeneration, M Male, F female, D diopters
Fig. 1 Measurement of subfoveal and peripapillary choroidal thickness (CT). Subfoveal CT (white arrow) was measured perpendicularly from the
outer surface of the line corresponding to the retinal pigment epithelium (RPE) to the inner chorioscleral junction (a). A 360°, 3.4-mm-diameter
circle scan provided retinal thickness (RT) and retinal nerve fiber layer (RNFL) thickness from four sectors around the optic disc. The thickness
value of each sector represents the mean thickness of the layers within each sector (b). The RT of each sector was determined between two
segmentation lines of the internal limiting membrane (ILM) and RPE. The segmentation line of the RPE was then modified to the chorioscleral
junction by the examiner using the modification tool in the optical coherence tomography image viewer program (c). Chorioretinal thickness
between the ILM and chorioscleral junction was obtained, and CT was calculated by subtracting the RT from the chorioretinal thickness of each
sector. T, temporal; S, superior; I, inferior; N, nasal
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peripapillary CT decreased at both 3 and 6 months, while
other areas showed no significant changes. Mean subfoveal
CT at baseline in the AMD group was significantly reduced
at 3 months and at 6 months (Table 3) (Figs. 2 and 3). The
difference in value or proportion of subfoveal and mean
peripapillary CT at 6 months was not associated with
the number of IVRs received (Pearson’s correlation test,
all, P > 0.05). Mean subfoveal CT and peripapillary CT
at both 3 and 6 months showed no significant differ-
ences when compared with the baseline values of the
normal controls. An additional file shows this in more
detail [Additional file 1].
By neovascularization type, the type 2 group showed de-
creased subfoveal CT at both 3 and 6 months (all, P < 0.05),
while the mean peripapillary CT showed no changes (all,
P > 0.05) (Table 4). The type 3 group showed a tendency
toward decreased subfoveal CT, but this was not seen in
mean peripapillary CT. Because of the small number of
type 3 cases, the statistical power was not available.
Thirty eyes (76.9 %) showed treatment response and nine
eyes (23.1 %) showed non-response. In univariate analysis, a
decreased proportion of both subfoveal CT and temporal
peripapillary CT were associated with treatment response
(Table 5). In multivariate analysis, only a decreased propor-
tion of subfoveal CT was associated with treatment re-
sponse (Table 6).
Retinal thickness and retinal nerve fiber layer thickness
CRT and temporal peripapillary RT of the AMD group
decreased at 3 months and at 6 months when compared
with the baseline values, while the mean RNFL thickness
showed no significant change 3 months or 6 months
after IVR (Table 3).
Table 2 Comparison of choroidal thickness between patients with
neovascular age-related macular degeneration and age-matched
controls
AMD group Control group P value*
(n = 39) (n = 39)
Subfoveal CT (μm) 228.6 ± 78.6 224.2 ± 54.7 0.775
Peripapillary CT (μm)
Mean 153.2 ± 45.3 148.2 ± 38.8 0.600
Superior 165.2 ± 49.5 160.3 ± 42.6 0.637
Nasal 153.2 ± 43.0 148.3 ± 36.5 0.591
Inferior 127.3 ± 40.0 122.7 ± 32.5 0.577
Temporal 167.1 ± 54.5 161.4 ± 49.8 0.635
Continuous variables are expressed as mean ± standard deviation
*Comparison of baseline parameters between the control group and AMD
group, P value was based on the student t-test
AMD age-related macular degeneration, CT choroidal thickness
Table 3 Changes in choroidal thickness, retinal thickness and retinal nerve fiber layer thickness during ranibizumab treatment
Baseline 3 months P value* 6 months P value*
Subfoveal CT (μm) 228.6 ± 78.6 213.8 ± 75.5 <0.001 214.1 ± 72.8 <0.001
Peripapillary CT (μm)
Mean 153.2 ± 45.3 149.6 ± 43.8 0.156 150.0 ± 43.4 0.187
Superior 165.2 ± 49.5 162.2 ± 48.7 0.252 162.6 ± 47.8 0.330
Nasal 153.2 ± 43.0 151.6 ± 43.3 0.532 150.8 ± 42.7 0.378
Inferior 127.3 ± 40.0 125.1 ± 38.3 0.321 125.9 ± 37.5 0.555
Temporal 167.1 ± 54.5 159.4 ± 50.8 0.010 160.6 ± 49.6 0.011
Central RT (μm) 300.4 ± 93.0 233.6 ± 62.0 0.001 232.9 ± 61.9 0.001
Peripapillary RT (μm)
Mean 282.8 ± 19.7 279.9 ± 22.1 0.009 279.8 ± 20.2 0.033
Superior 303.0 ± 28.3 301.6 ± 30.1 0.169 300.7 ± 26.9 0.171
Nasal 250.4 ± 22.1 251.0 ± 26.7 0.732 251.0 ± 22.9 0.812
Inferior 300.4 ± 22.0 300.2 ± 24.8 0.829 298.2 ± 22.7 0.246
Temporal 276.8 ± 21.2 267.0 ± 20.1 <0.001 269.3 ± 21.9 0.015
RNFL thickness (μm)
Mean 111.7 ± 11.4 112.9 ± 10.6 0.666 113.1 ± 11.9 0.611
Superior 130.4 ± 17.5 131.8 ± 16.3 0.736 134.0 ± 16.4 0.373
Nasal 89.3 ± 15.8 92.2 ± 18.9 0.478 90.4 ± 19.3 0.790
Inferior 135.1 ± 16.9 137.9 ± 17.0 0.439 138.6 ± 18.9 0.350
Temporal 92.1 ± 16.2 89.4 ± 13.4 0.379 89.4 ± 16.0 0.385
Continuous variables are expressed as mean ± standard deviation
*Comparison of the parameters in each AMD group visit; P value was based on the paired t-test
CT choroidal thickness, RT retinal thickness, RNFL retinal nerve fiber layer
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Interobserver reliability
Interobserver reliability was assessed by analysis of intra-
class correlation coefficients. The intraclass correlation
coefficients ranged from 0.940 to 0.984. An additional
file shows this in more detail [Additional file 2].
Discussion
In this study, macular and peripapillary CT in the AMD
group did not differ from those in the control group at
baseline. The macular CT results in AMD patients and
normal controls are consistent with those found in pre-
vious studies, which revealed no significant differences
between AMD eyes and normal eyes [11–13]. Because it
has been suggested that AMD is a vascular disorder
associated with altered blood flow in the choroid [6, 7],
we wondered if there were regional differences in CT
between the macula and outside of the macula. However,
we found no such difference in CT between the macula
and outside of the macula in the neovascular AMD and
control groups.
Peripapillary CT outside of the macula did not change
after IVR at 6 months. These findings differed from the
subfoveal choroid results. In this study, both subfoveal
CT and temporal peripapillary CT decreased after three
monthly IVRs, and the reduction in CT was sustained
for 6 months. CT outside of the macula, including
superior, nasal and inferior peripapillary CT, was not
affected by IVR. Even though there was a trend toward a
reduction in PCT in all sectors, these differences were
not statistically significant. This may indicate that ranibi-
zumab affects the choroid under and around the macula
but not the choroid outside of the macula. We did not
investigate the change in CT in AMD eyes without treat-
ment. Therefore, the results of our study could not confirm
Fig. 2 Changes in subfoveal choroidal thickness (SFCT) in a 74-year-old woman with neovascular age-related macular degeneration. SD-OCT image at
baseline (a) showed subretinal fluid accumulation in the macula. After three consecutive monthly injections of ranibizumab, the subretinal fluid
disappeared, and the SFCT decreased as compared with the baseline (b). At 6 months, the SFCT was still lower compared with baseline (c)
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if choroidal thinning of the subfoveal area is directly in-
duced by the IVR or by the disease course of AMD. How-
ever, the results of the current study may suggest that the
CT outside of the macula is not involved in the change in
CT after IVR in eyes with AMD.
In the current study, subfoveal CT decreased after IVR, a
result consistent with previous studies [14, 15]. Yamazaki et
al. suggested that IVR may have a pharmacologic effect on
the choroid underneath the CNV lesion [15]. Changes in
CT associated with IVR may be explained by two possible
Fig. 3 Changes in peripapillary choroidal thickness (PCT) of the patient shown in Fig. 2. Peripapillary circle scans at baseline (a), 3 months (b) and
6 months after the intravitreal injection of ranibizumab (c). Nasal PCT at baseline (142 μm) was not changed at 3 months (146 μm) and 6 months
(142 μm), while temporal PCT at baseline (133 μm) decreased at 3 months (121 μm) and 6 months (117 μm). T, temporal; S, superior; I, inferior; N, nasal
Table 4 Changes in choroidal thickness during ranibizumab treatment according to neovascularization type
Baseline 3 months P value* 6 months P value*
Type 2 Subfoveal CT (μm) 238.7 ± 75.8 223.4 ± 72.4 <0.001 224.0 ± 68.5 0.002
(n = 35) Peripapillary CT (μm)
Mean 157.3 ± 45.1 153.3 ± 43.1 0.154 153.4 ± 42.6 0.163
Superior 168.8 ± 47.9 165.6 ± 46.3 0.266 165.9 ± 45.3 0.313
Nasal 155.9 ± 43.7 154.1 ± 43.5 0.511 153.2 ± 42.4 0.340
Inferior 131.7 ± 39.8 129.2 ± 38.1 0.285 129.9 ± 38.3 0.456
Temporal 172.5 ± 53.6 164.4 ± 49.4 0.011 164.5 ± 49.2 0.010
Type 3 Subfoveal CT (μm) 145.0 (102.8, 171.2) 124.0 (89.5, 175.8) N/A 117.0 (83.4, 182.5) N/A
(n = 4) Peripapillary CT (μm)
Mean 112.6 (89.3, 150.8) 117.0 (80.0, 152.5) N/A 117.0 (83.8, 182.5) N/A
Superior 125.0 (82.5, 193.8) 129.0 (72.8, 194.3) N/A 131.0 (75.0, 195.3) N/A
Nasal 132.5 (98.5, 156.0) 129.5 (91.0, 167.3) N/A 128.0 (87.5, 173.0) N/A
Inferior 88.5 (83.0, 93.3) 84.5 (77.8, 104.0) N/A 84.5 (77.8, 110.0) N/A
Temporal 112.5 (84.0, 161.3) 116.5 (71.5, 160.0) N/A 117.0 (71.3, 162.8) N/A
Continuous variables are expressed as mean ± standard deviation or median (interquartile range)
*Comparison of parameters in each AMD group visit; P value was based on paired t-test
CT choroidal thickness, N/A not applicable
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mechanisms. First, decreased intraocular VEGF after IVR
might affect the CT. VEGF is known to be associated with
vasculogenesis and blood vessel hyperpermeability [35–37].
Hypoxia and ischemia of RPE from inadequate choroidal
perfusion might produce VEGF, which may lead to neovas-
cular AMD [38]. Both the subfoveal choroid and the peri-
papillary choroid may be affected by increased VEGF.
Although the natural course of CT in neovascular AMD is
unknown, vasodilatation may be expected in the choroid of
neovascular AMD eyes, as VEGF is associated with vascular
permeability [36, 37]. After a decrease in intraocular VEGF
levels due to IVR, changes in vascular permeability and CT
in both the macular and peripapillary region may follow. In
this study, the changes in macular and temporal peripapil-
lary CT were significant while CT outside of macula
showed no significant changes. This might suggest that IVR
mainly affects the abnormal CNV and the hyperpermeabil-
ity associated with the CNV under and around the macula.
In addition, vasoconstriction of the choroid after IVR may
affect CT. Although the effect of VEGF on choroidal struc-
ture, thickness and large vessels is not clearly defined,
VEGF is known to be essential for the development of the
choroid and maintenance of the choriocapillaries [39, 40].
Furthermore, the vasoconstrictive effect of ranibizumab
might affect the choroidal vessels and thickness [41, 42]. In
this study, a significant change in CT was observed only in
the macular and temporal peripapillary areas. Thus, even
though we cannot exclude the vasoconstrictive effect of
IVR on the macula, IVR does not result in a change of CT
outside of the macula.
In this study, decreased proportions of subfoveal and
temporal peripapillary CT were associated with treatment
response after three monthly doses of ranibizumab. How-
ever, in multivariate analysis, a decreased proportion of
subfoveal CT was a factor associated with treatment re-
sponse, which might result from the positive correlation
between a decreased proportion of subfoveal CT and tem-
poral peripapillary CT. This may suggest that decreased
hyperpermeability or vasoconstriction and regression of
CNV after IVR change the choroid under and around the
macula. However, we cannot conclude whether decreased
CT is a preceding factor associated with treatment response
or if decreased CT is a result of treatment response, as the
decreased ratio of CT is not a preoperative finding but
rather a parameter that is calculated from CT before and
after IVR.
However, the observed decrease in CT is insufficient
to limit the clinical use of ranibizumab. In the present
study, although macular and temporal peripapillary CT
were decreased at 3 and 6 months after IVR when com-
pared to the initial CT, the reduction in CT was rela-
tively small, and was not associated with a loss of BCVA.
In addition, CT after IVR at 3 and 6 months was not
different from that of the normal controls. In addition,
the non-significant changes in CT outside of the macula
suggest that the effect of IVRs outside of the macula is
minimal. IVRs decreased temporal peripapillary RT, but
Table 5 Univariate analysis for estimating factors associated with a 3-month response after intravitreal injection of ranibizumab
Variables P value* OR (95 % CI)
Sex (male) 0.521 1.635 (0.365–7.326)
Age (years) 0.945 1.004 (0.894–1.128)
Eye (OD) 0.237 0.400 (0.088–1.826)
Lens status (phakic eye) 1.000 N/A
Baseline subfoveal CT (μm) 0.296 0.994 (0.984–1.005)
Baseline mean peripapillary CT (μm) 0.789 0.998 (0.981–1.015)
Decreased amount of subfoveal CT (μm) 0.097 1.030 (0.995–1.066)
Decreased proportion of subfoveal CT (%) 0.007 1.124 (1.033–1.223)
Decreased amount of mean peripapillary CT (μm) 0.094 1.041 (0.993–1.092)
Decreased proportion of mean peripapillary CT (%) 0.077 1.055 (0.994–1.120)
Decreased amount of mean temporal peripapillary CT (μm) 0.061 1.043 (0.998–1.090)
Decreased proportion of mean temporal peripapillary CT (%) 0.029 1.070 (1.007–1.137)
*P value based on logistic regression analysis
OD oculus dexter, CT choroidal thickness, N/A not applicable
Table 6 Multivariate analysis for estimating factors associated
with a 3-month response after intravitreal injection of ranibizumab
Variables P value* OR (95 % CI)
Sex (male) 0.511 1.879 (0.287–12.306)








*P value based on logistic regression analysis
CT choroidal thickness
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may be associated with a decrease in CRT. The RT of
other peripapillary areas and RNFL thickness were not
affected by IVRs.
In the control group, the subfoveal CT and peripapillary
CT showed a negative relationship with age. Previous stud-
ies have demonstrated that the subfoveal CT of normal
controls and patients with dry AMD are correlated with
age, but the eyes with neovascular AMD demonstrated a
weaker correlation between subfoveal CT and age [13, 34].
The peripapillary CT was also related to age and had a
negative correlation with the results from our previously
reported study [33]. In this study, the normal control group
showed a negative correlation between subfoveal and peri-
papillary CT and age, but the neovascular AMD group
showed no correlation between subfoveal and peripapillary
CT and age. This absent relationship between subfoveal CT
and age might suggest an alteration in the choroid of the
macula in neovascular AMD and may provide additional
insight into the pathogenesis of neovascular AMD [15].
This study has several limitations. First, because it is a
retrospective study with short-term results and contains
a small number of cases, our study may have limited
generalizability. We could not see a short-term change
in CT 1 month after IVR, and it is insufficient to draw
conclusions on the long-term effect of IVR on the chor-
oid based on the short follow-up period. Further studies
with larger sample sizes and longer study periods are
needed. Second, because of the retrospective nature of
this study, diurnal variation of CT was not considered.
Mean diurnal variation of subfoveal CT in healthy indi-
viduals is about 33.7 μm and the diurnal variation of the
peripapillary CT remains unclear [43]. The changes in
the mean macular and peripapillary CT in this study
were relatively small, and the changes in macular CT
were less than those expected from diurnal variation.
Although most patients visited the outpatient clinic
during the day, this study did not adjust for diurnal
changes in CT. Third, we could not obtain information
about refractive error and axial length in all patients.
Two patients in the AMD group and four patients in the
control group with pseudophakia had no information
available on refractive error, although the axial length in
all of these patients was less than 26.0 mm. Because axial
length and refractive error are known to be associated with
subfoveal CT and peripapillary CT, the lack of this infor-
mation in the analysis is a shortcoming of this study.
Fourth, although CT measurements were performed by
two independent examiners, the method was manual as no
automated method exists. Fifth, we only matched patients
by age, but not by sex. Although there were no differences
in these characteristics between the two patient groups,
the results may still be affected. Sixth, we only measured
CT of the peripapillary or macular region. It could not
represent CT beyond the posterior pole. Finally, because
the treatment was based on monthly dosing and a PRN
schedule, the number of injections received at 6 months
differed among patients. However, there was no significant
correlation between the difference in subfoveal or peripa-
pillary CT at 6 months and the number of injections.
Conclusions
The mean peripapillary CT of the AMD group was not
significantly different from that of the age-matched con-
trols. Apart from the CT in the macular area, the mean
peripapillary CT and peripapillary CT outside of the macula
did not change 6 months after IVR. This result may suggest
that the change in CT after IVR may be limited to the
macula in eyes with neovascular AMD.
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